The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval a Type II variation for Rubraca (rucaparib), as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.
New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in...
